Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2018, 36830-36834 [2017-16439]
Download as PDF
36830
Federal Register / Vol. 82, No. 150 / Monday, August 7, 2017 / Notices
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–471N]
Proposed Aggregate Production
Quotas for Schedule I and II Controlled
Substances and Assessment of
Annual Needs for the List I Chemicals
Ephedrine, Pseudoephedrine, and
Phenylpropanolamine for 2018
Drug Enforcement
Administration, Department of Justice.
ACTION: Notice with request for
comments.
AGENCY:
The Drug Enforcement
Administration (DEA) proposes to
establish the 2018 aggregate production
quotas for controlled substances in
schedules I and II of the Controlled
Substances Act and assessment of
annual needs for the list I chemicals
ephedrine, pseudoephedrine, and
phenylpropanolamine.
SUMMARY:
Interested persons may file
written comments on this notice in
accordance with 21 CFR 1303.11(c) and
1315.11(d). Electronic comments must
be submitted, and written comments
must be postmarked, on or before
September 6, 2017. Commenters should
be aware that the electronic Federal
Docket Management System will not
accept comments after 11:59 p.m.
Eastern Time on the last day of the
comment period.
Based on comments received in
response to this notice, the
Administrator may hold a public
hearing on one or more issues raised. In
the event the Administrator decides in
his sole discretion to hold such a
hearing, the Administrator will publish
a notice of any such hearing in the
Federal Register. After consideration of
any comments or objections, or after a
hearing, if one is held, the
Administrator will publish in the
Federal Register a final order
establishing the 2018 aggregate
production quotas for schedule I and II
controlled substances, and an
assessment of annual needs for the list
I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine.
DATES:
To ensure proper handling
of comments, please reference ‘‘Docket
No. DEA–471N’’ on all correspondence,
including any attachments. The Drug
Enforcement Administration encourages
that all comments be submitted
electronically through the Federal
eRulemaking Portal which provides the
ability to type short comments directly
into the comment field on the Web page
mstockstill on DSK30JT082PROD with NOTICES
ADDRESSES:
VerDate Sep<11>2014
18:14 Aug 04, 2017
Jkt 241001
or attach a file for lengthier comments.
Please go to https://www.regulations.gov
and follow the online instructions at
that site for submitting comments. Upon
completion of your submission you will
receive a Comment Tracking Number for
your comment. Please be aware that
submitted comments are not
instantaneously available for public
view on Regulations.gov. If you have
received a Comment Tracking Number,
your comment has been successfully
submitted and there is no need to
resubmit the same comment. Paper
comments that duplicate electronic
submissions are not necessary and are
discouraged. Should you wish to mail a
paper comment in lieu of an electronic
comment, it should be sent via regular
or express mail to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152.
FOR FURTHER INFORMATION CONTACT:
Michael J. Lewis, Diversion Control
Division, Drug Enforcement
Administration; Mailing Address: 8701
Morrissette Drive, Springfield, Virginia
22152, Telephone: (202) 598–6812.
SUPPLEMENTARY INFORMATION:
Posting of Public Comments
Please note that all comments
received in response to this docket are
considered part of the public record.
They will, unless reasonable cause is
given, be made available by the Drug
Enforcement Administration (DEA) for
public inspection online at https://
www.regulations.gov. Such information
includes personal identifying
information (such as your name,
address, etc.) voluntarily submitted by
the commenter.
The Freedom of Information Act
(FOIA) applies to all comments
received. If you want to submit personal
identifying information (such as your
name, address, etc.) as part of your
comment, but do not want it to be made
publicly available, you must include the
phrase ‘‘PERSONAL IDENTIFYING
INFORMATION’’ in the first paragraph
of your comment. You must also place
all the personal identifying information
you do not want made publicly
available in the first paragraph of your
comment and identify what information
you want redacted.
If you want to submit confidential
business information as part of your
comment, but do not want it to be made
publicly available, you must include the
phrase ‘‘CONFIDENTIAL BUSINESS
INFORMATION’’ in the first paragraph
of your comment. You must also
prominently identify confidential
PO 00000
Frm 00103
Fmt 4703
Sfmt 4703
business information to be redacted
within the comment.
Comments containing personal
identifying information or confidential
business information identified and
located as directed above will generally
be made available in redacted form. If a
comment contains so much confidential
business information or personal
identifying information that it cannot be
effectively redacted, all or part of that
comment may not be made publicly
available. Comments posted to https://
www.regulations.gov may include any
personal identifying information (such
as name, address, and phone number)
included in the text of your electronic
submission that is not identified as
directed above as confidential.
An electronic copy of this document
is available at https://
www.regulations.gov for easy reference.
Legal Authority
Section 306 of the Controlled
Substances Act (CSA) (21 U.S.C. 826)
requires the Attorney General to
establish aggregate production quotas
for each basic class of controlled
substance listed in schedules I and II
and for the list I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine. The Attorney
General has delegated this function to
the Administrator of the DEA pursuant
to 28 CFR 0.100.
Analysis for Proposed 2018 Aggregate
Production Quotas and Assessment of
Annual Needs
The proposed year 2018 aggregate
production quotas and assessment of
annual needs represent those quantities
of schedule I and II controlled
substances, and the list I chemicals
ephedrine, pseudoephedrine, and
phenylpropanolamine, to be
manufactured in the United States in
2018 to provide for the estimated
medical, scientific, research, and
industrial needs of the United States,
lawful export requirements, and the
establishment and maintenance of
reserve stocks. These quotas include
imports of ephedrine, pseudoephedrine,
and phenylpropanolamine, but do not
include imports of controlled
substances for use in industrial
processes.
In determining the proposed 2018
aggregate production quotas and
assessment of annual needs, the Acting
Administrator has taken into account
the criteria pursuant to 21 U.S.C. 826(a)
and in accordance with 21 CFR 1303.11
(aggregate production quotas for
controlled substances) and 21 CFR
1315.11 (assessment of annual needs for
ephedrine, pseudoephedrine, and
E:\FR\FM\07AUN1.SGM
07AUN1
Federal Register / Vol. 82, No. 150 / Monday, August 7, 2017 / Notices
phenylpropanolamine). The DEA
proposes the aggregate production
quotas and assessment of annual needs
for 2018 by considering: (1) Total net
disposal of each class or chemical by all
manufacturers and chemical importers
during the current and two preceding
years; (2) trends in the national rate of
net disposal of the class or chemical; (3)
total actual (or estimated) inventories of
the class or chemical and of all
substances manufactured from the class
or chemical, and trends in inventory
accumulation; (4) projected demand for
each class or chemical as indicated by
procurement and import quotas
requested in accordance with 21 CFR
1303.12, 1315.32, and 1315.34; and (5)
other factors affecting medical,
scientific, research, and industrial needs
of the United States and lawful export
requirements, as the Acting
Administrator finds relevant. These
quotas do not include imports of
controlled substances for use in
industrial processes.
Other factors the Acting
Administrator considered in calculating
the aggregate production quotas, but not
the assessment of annual needs, include
product development requirements of
both bulk and finished dosage form
manufacturers, and other pertinent
information. In determining the
36831
proposed 2018 assessment of annual
needs, the DEA used the calculation
methodology previously described in
the 2010 and 2011 assessment of annual
needs (74 FR 60294, Nov. 20, 2009, and
75 FR 79407, Dec. 20, 2010,
respectively).
The Acting Administrator, therefore,
proposes to establish the 2018 aggregate
production quotas for certain schedule I
and II controlled substances and
assessment of annual needs for the list
I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine, expressed in
grams of anhydrous acid or base, as
follows:
Proposed
2018
quotas
Basic class
(g)
mstockstill on DSK30JT082PROD with NOTICES
Schedule I
1-(1-Phenylcyclohexyl)pyrrolidine ........................................................................................................................................................
1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201) ............................................................................................................................
1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694) ...........................................................................................................................
1-[1-(2-Thienyl)cyclohexyl]piperidine ...................................................................................................................................................
1-Benzylpiperazine ..............................................................................................................................................................................
1-Methyl-4-phenyl-4-propionoxypiperidine ...........................................................................................................................................
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E) ...........................................................................................................................
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D) ........................................................................................................................
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N) ..........................................................................................................................
2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C-P) ......................................................................................................................
2-(2,5-Dimethoxyphenyl)ethanamine (2C-H) .......................................................................................................................................
2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36) ........................
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C) ........................................................................................................................
2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82) ........................
2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I) ..............................................................................................................................
2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5) ..................................
2,5-Dimethoxy-4-ethylamphetamine (DOET) ......................................................................................................................................
2,5-Dimethoxy-4-n-propylthiophenethylamine .....................................................................................................................................
2,5-Dimethoxyamphetamine ................................................................................................................................................................
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2) ................................................................................................................
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4) ..........................................................................................................
3,4,5-Trimethoxyamphetamine ............................................................................................................................................................
3,4-Methylenedioxyamphetamine (MDA) ............................................................................................................................................
3,4-Methylenedioxymethamphetamine (MDMA) .................................................................................................................................
3,4-Methylenedioxy-N-ethylamphetamine (MDEA) .............................................................................................................................
3,4-Methylenedioxy-N-methylcathinone (methylone) ..........................................................................................................................
3,4-Methylenedioxypyrovalerone (MDPV) ...........................................................................................................................................
3-FMC; 3-Fluoro-N-methylcathinone ...................................................................................................................................................
3-Methylfentanyl ...................................................................................................................................................................................
3-Methylthiofentanyl .............................................................................................................................................................................
4-Bromo-2,5-dimethoxyamphetamine (DOB) ......................................................................................................................................
4-Bromo-2,5-dimethoxyphenethylamine (2-CB) ..................................................................................................................................
4-Fluoroisobutyryl fentanyl ...................................................................................................................................................................
4-FMC; Flephedrone ............................................................................................................................................................................
4-MEC; 4-Methyl-N-ethylcathinone ......................................................................................................................................................
4-Methoxyamphetamine ......................................................................................................................................................................
4-Methyl-2,5-dimethoxyamphetamine (DOM) ......................................................................................................................................
4-Methylaminorex ................................................................................................................................................................................
4-Methyl-N-methylcathinone (mephedrone) ........................................................................................................................................
4-Methyl-a-pyrrolidinopropiophenone (4-MePPP) ...............................................................................................................................
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol .........................................................................................................
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP-47,497 C8-homolog) ...........................
5F-ADB; 5F-MDMB-PINACA (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) ............................
5F-AMB (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate) ...................................................................
5F-APINACA; 5F-AKB48 (N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide) ........................................................
5-Fluoro-PB-22; 5F-PB-22 ...................................................................................................................................................................
5-Fluoro-UR144, XLR11 ([1-(5-fluoro-pentyl)-1Hindol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone ............................................
5-Methoxy-3,4-methylenedioxyamphetamine ......................................................................................................................................
5-Methoxy-N,N-diisopropyltryptamine ..................................................................................................................................................
VerDate Sep<11>2014
18:14 Aug 04, 2017
Jkt 241001
PO 00000
Frm 00104
Fmt 4703
Sfmt 4703
E:\FR\FM\07AUN1.SGM
07AUN1
10
30
30
15
25
2
30
30
30
30
30
25
30
25
30
30
25
25
25
30
30
25
55
50
40
40
35
25
30
30
25
25
30
25
25
150
25
25
45
25
50
40
30
30
30
20
25
25
25
36832
Federal Register / Vol. 82, No. 150 / Monday, August 7, 2017 / Notices
Proposed
2018
quotas
Basic class
mstockstill on DSK30JT082PROD with NOTICES
(g)
5-Methoxy-N,N-dimethyltryptamine .....................................................................................................................................................
AB-CHMINACA ....................................................................................................................................................................................
AB-FUBINACA .....................................................................................................................................................................................
AB-PINACA ..........................................................................................................................................................................................
ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) ..................................
Acetyl Fentanyl ....................................................................................................................................................................................
Acetyl-alpha-methylfentanyl .................................................................................................................................................................
Acetyldihydrocodeine ...........................................................................................................................................................................
Acetylmethadol ....................................................................................................................................................................................
ADB-PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) ......................................................
AH-7921 ...............................................................................................................................................................................................
Allylprodine ..........................................................................................................................................................................................
Alphacetylmethadol ..............................................................................................................................................................................
alpha-Ethyltryptamine ..........................................................................................................................................................................
Alphameprodine ...................................................................................................................................................................................
Alphamethadol .....................................................................................................................................................................................
alpha-Methylfentanyl ............................................................................................................................................................................
alpha-Methylthiofentanyl ......................................................................................................................................................................
alpha-Methyltryptamine (AMT) ............................................................................................................................................................
alpha-Pyrrolidinobutiophenone (a-PBP) ..............................................................................................................................................
alpha-Pyrrolidinopentiophenone (a-PVP) ............................................................................................................................................
Aminorex ..............................................................................................................................................................................................
APINCA, AKB48 (N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide) .........................................................................................
Benzylmorphine ...................................................................................................................................................................................
Betacetylmethadol ...............................................................................................................................................................................
beta-Hydroxy-3-methylfentanyl ............................................................................................................................................................
beta-Hydroxyfentanyl ...........................................................................................................................................................................
beta-Hydroxythiofentanyl .....................................................................................................................................................................
Betameprodine .....................................................................................................................................................................................
Betamethadol .......................................................................................................................................................................................
Betaprodine ..........................................................................................................................................................................................
Bufotenine ............................................................................................................................................................................................
Butylone ...............................................................................................................................................................................................
Butyryl fentanyl ....................................................................................................................................................................................
Cathinone .............................................................................................................................................................................................
Codeine methylbromide .......................................................................................................................................................................
Codeine-N-oxide ..................................................................................................................................................................................
Desomorphine ......................................................................................................................................................................................
Diethyltryptamine .................................................................................................................................................................................
Difenoxin ..............................................................................................................................................................................................
Dihydromorphine ..................................................................................................................................................................................
Dimethyltryptamine ..............................................................................................................................................................................
Dipipanone ...........................................................................................................................................................................................
Etorphine ..............................................................................................................................................................................................
Fenethylline ..........................................................................................................................................................................................
Furanyl fentanyl ...................................................................................................................................................................................
gamma-Hydroxybutyric acid ................................................................................................................................................................
Heroin ..................................................................................................................................................................................................
Hydromorphinol ....................................................................................................................................................................................
Hydroxypethidine .................................................................................................................................................................................
Ibogaine ...............................................................................................................................................................................................
JWH-018 and AM678 (1-Pentyl-3-(1-naphthoyl)indole) ......................................................................................................................
JWH-019 (1-Hexyl-3-(1-naphthoyl)indole) ...........................................................................................................................................
JWH-073 (1-Butyl-3-(1-naphthoyl)indole) ............................................................................................................................................
JWH-081 (1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole) .......................................................................................................................
JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole) ...........................................................................................................................
JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole) ...............................................................................................................
JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole) ............................................................................................................................
JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole) ........................................................................................................................
JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole) ............................................................................................................................
Lysergic acid diethylamide (LSD) ........................................................................................................................................................
MAB-CHMINACA;
ADB-CHMINACA
(N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3carboxamide) ....................................................................................................................................................................................
MDMB-CHMICA; MMB-CHMINACA (methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate) ...............
MDMB-FUBINACA (methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) ...........................................
Marihuana ............................................................................................................................................................................................
Mecloqualone .......................................................................................................................................................................................
Mescaline .............................................................................................................................................................................................
Methaqualone ......................................................................................................................................................................................
Methcathinone .....................................................................................................................................................................................
VerDate Sep<11>2014
18:14 Aug 04, 2017
Jkt 241001
PO 00000
Frm 00105
Fmt 4703
Sfmt 4703
E:\FR\FM\07AUN1.SGM
07AUN1
25
30
50
30
30
100
30
30
2
50
30
2
2
25
2
2
30
30
25
25
25
25
25
30
2
30
30
30
2
4
2
3
25
30
24
30
192
25
25
8,225
1,000,160
35
5
30
30
30
37,130,000
45
40
2
30
35
45
45
30
30
35
30
30
30
40
30
30
30
443,680
30
25
60
25
Federal Register / Vol. 82, No. 150 / Monday, August 7, 2017 / Notices
36833
Proposed
2018
quotas
Basic class
(g)
Methyldesorphine .................................................................................................................................................................................
Methyldihydromorphine ........................................................................................................................................................................
Morphine methylbromide .....................................................................................................................................................................
Morphine methylsulfonate ....................................................................................................................................................................
Morphine-N-oxide ................................................................................................................................................................................
N,N-Dimethylamphetamine ..................................................................................................................................................................
Naphyrone ...........................................................................................................................................................................................
N-Ethyl-1-phenylcyclohexylamine ........................................................................................................................................................
N-Ethylamphetamine ...........................................................................................................................................................................
N-Hydroxy-3,4-methylenedioxyamphetamine ......................................................................................................................................
Noracymethadol ...................................................................................................................................................................................
Norlevorphanol .....................................................................................................................................................................................
Normethadone .....................................................................................................................................................................................
Normorphine ........................................................................................................................................................................................
Para-fluorofentanyl ...............................................................................................................................................................................
Parahexyl .............................................................................................................................................................................................
PB-22; QUPIC .....................................................................................................................................................................................
Pentedrone ..........................................................................................................................................................................................
Pentylone .............................................................................................................................................................................................
Phenomorphan ....................................................................................................................................................................................
Pholcodine ...........................................................................................................................................................................................
Psilocybin .............................................................................................................................................................................................
Psilocyn ................................................................................................................................................................................................
SR-18 and RCS-8 (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole) ...........................................................................................
SR-19 and RCS-4 (1-Pentyl-3-[(4-methoxy)-benzoyl]indole) ..............................................................................................................
Tetrahydrocannabinols ........................................................................................................................................................................
Thiofentanyl .........................................................................................................................................................................................
THJ-2201 ([1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone) ......................................................................................
Tilidine ..................................................................................................................................................................................................
Trimeperidine .......................................................................................................................................................................................
UR-144 (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone ......................................................................................
U-47700 ...............................................................................................................................................................................................
5
2
5
5
150
25
25
5
24
24
2
55
2
40
25
5
20
25
25
2
5
30
50
45
30
384,460
25
30
25
2
25
30
mstockstill on DSK30JT082PROD with NOTICES
Schedule II
1-Phenylcyclohexylamine ....................................................................................................................................................................
1-Piperidinocyclohexanecarbonitrile ....................................................................................................................................................
4-Anilino-N-phenethyl-4-piperidine (ANPP) .........................................................................................................................................
Alfentanil ..............................................................................................................................................................................................
Alphaprodine ........................................................................................................................................................................................
Amobarbital ..........................................................................................................................................................................................
Amphetamine (for conversion) ............................................................................................................................................................
Amphetamine (for sale) .......................................................................................................................................................................
Carfentanil ............................................................................................................................................................................................
Cocaine ................................................................................................................................................................................................
Codeine (for conversion) .....................................................................................................................................................................
Codeine (for sale) ................................................................................................................................................................................
Dextropropoxyphene ............................................................................................................................................................................
Dihydrocodeine ....................................................................................................................................................................................
Dihydroetorphine ..................................................................................................................................................................................
Diphenoxylate (for conversion) ............................................................................................................................................................
Diphenoxylate (for sale) .......................................................................................................................................................................
Ecgonine ..............................................................................................................................................................................................
Ethylmorphine ......................................................................................................................................................................................
Etorphine hydrochloride .......................................................................................................................................................................
Fentanyl ...............................................................................................................................................................................................
Glutethimide .........................................................................................................................................................................................
Hydrocodone (for conversion) .............................................................................................................................................................
Hydrocodone (for sale) ........................................................................................................................................................................
Hydromorphone ...................................................................................................................................................................................
Isomethadone ......................................................................................................................................................................................
Levo-alphacetylmethadol (LAAM) ........................................................................................................................................................
Levomethorphan ..................................................................................................................................................................................
Levorphanol .........................................................................................................................................................................................
Lisdexamfetamine ................................................................................................................................................................................
Meperidine ...........................................................................................................................................................................................
Meperidine Intermediate—A ................................................................................................................................................................
Meperidine Intermediate—B ................................................................................................................................................................
Meperidine Intermediate—C ................................................................................................................................................................
Metazocine ...........................................................................................................................................................................................
Methadone (for sale) ...........................................................................................................................................................................
VerDate Sep<11>2014
18:14 Aug 04, 2017
Jkt 241001
PO 00000
Frm 00106
Fmt 4703
Sfmt 4703
E:\FR\FM\07AUN1.SGM
07AUN1
4
4
1,342,320
2,538
2
18,894
11,280,000
39,856,000
20
92,120
15,040,000
40,015,800
35
264,140
2
14,100
770,800
88,134
30
32
1,342,320
2
114,680
50,348,280
4,547,720
30
5
30
12,126
17,869,000
2,717,540
5
30
5
15
22,278,000
36834
Federal Register / Vol. 82, No. 150 / Monday, August 7, 2017 / Notices
Proposed
2018
quotas
Basic class
(g)
Methadone Intermediate ......................................................................................................................................................................
Methamphetamine ...............................................................................................................................................................................
24,064,000
1,446,754
[900,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 600,000 grams for methamphetamine mostly for
conversion to a schedule III product; and 39,100 grams for methamphetamine (for sale)]
Methylphenidate ...................................................................................................................................................................................
Morphine (for conversion) ....................................................................................................................................................................
Morphine (for sale) ..............................................................................................................................................................................
Nabilone ...............................................................................................................................................................................................
Noroxymorphone (for conversion) .......................................................................................................................................................
Noroxymorphone (for sale) ..................................................................................................................................................................
Opium (powder) ...................................................................................................................................................................................
Opium (tincture) ...................................................................................................................................................................................
Oripavine ..............................................................................................................................................................................................
Oxycodone (for conversion) ................................................................................................................................................................
Oxycodone (for sale) ...........................................................................................................................................................................
Oxymorphone (for conversion) ............................................................................................................................................................
Oxymorphone (for sale) .......................................................................................................................................................................
Pentobarbital ........................................................................................................................................................................................
Phenazocine ........................................................................................................................................................................................
Phencyclidine .......................................................................................................................................................................................
Phenmetrazine .....................................................................................................................................................................................
Phenylacetone .....................................................................................................................................................................................
Racemethorphan .................................................................................................................................................................................
Racemorphan ......................................................................................................................................................................................
Remifentanil .........................................................................................................................................................................................
Secobarbital .........................................................................................................................................................................................
Sufentanil .............................................................................................................................................................................................
Tapentadol ...........................................................................................................................................................................................
Thebaine ..............................................................................................................................................................................................
60,724,000
4,089,000
33,958,440
17,860
14,044,540
376,000
84,600
564,000
24,534,000
2,453,400
95,692,000
20,962,000
3,395,280
25,850,000
5
35
25
40
5
5
2,820
161,682
1,880
18,388,280
94,000,000
List I Chemicals
Ephedrine (for conversion) ..................................................................................................................................................................
Ephedrine (for sale) .............................................................................................................................................................................
Phenylpropanolamine (for conversion) ................................................................................................................................................
Phenylpropanolamine (for sale) ...........................................................................................................................................................
Pseudoephedrine (for conversion) ......................................................................................................................................................
Pseudoephedrine (for sale) .................................................................................................................................................................
The Acting Administrator further
proposes that aggregate production
quotas for all other schedule I and II
controlled substances included in 21
CFR 1308.11 and 1308.12 remain at
zero. In accordance with 21 CFR
1303.13 and 21 CFR 1315.13, upon
consideration of the relevant factors, the
Acting Administrator may adjust the
2018 aggregate production quotas and
assessment of annual needs as needed.
mstockstill on DSK30JT082PROD with NOTICES
Conclusion
After consideration of any comments
or objections, or after a hearing, if one
is held, the Acting Administrator will
issue and publish in the Federal
Register a final order establishing the
2018 aggregate production quota for
controlled substances in schedules I and
II and establishing an assessment of
annual needs for the list I chemicals
ephedrine, pseudoephedrine, and
phenylpropanolamine, 21 CFR
1303.11(c) and 1315.11(f).
VerDate Sep<11>2014
18:14 Aug 04, 2017
Jkt 241001
Dated: July 27, 2017.
Chuck Rosenberg,
Acting Administrator.
[FR Doc. 2017–16439 Filed 8–4–17; 8:45 am]
BILLING CODE 4410–09–P
47,000
4,136,000
14,100,000
7,990,000
40
169,200,000
following information collection request
to the Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995.
DEPARTMENT OF JUSTICE
Comments are encouraged and
will be accepted for 60 days until
October 6, 2017.
[OMB Number 1110–0051]
FOR FURTHER INFORMATION CONTACT:
DATES:
Agency Information Collection
Activities; Proposed eCollection
eComments Requested; Revision of a
Currently Approved Collection; Final
Disposition Report (R–84)
Criminal Justice Information
Services Division, Federal Bureau of
Investigation, Department of Justice.
ACTION: 60-day notice.
AGENCY:
Department of Justice (DOJ),
Federal Bureau of Investigation,
Criminal Justice Information Services
Division will be submitting the
SUMMARY:
PO 00000
Frm 00107
Fmt 4703
Sfmt 4703
If
you have additional comments
especially on the estimated public
burden or associated response time,
suggestions, or need a copy of the
proposed information collection
instrument with instructions or
additional information, please contact
Gerry Lynn Brovey, Supervisory
Information Liaison Specialist, FBI,
CJIS, Resources Management Section,
Administrative Unit, Module C–2, 1000
Custer Hollow Road, Clarksburg, West
Virginia 26306 (facsimile: 304–625–
5093) or email glbrovey@ic.fbi.gov.
Written comments and/or suggestions
E:\FR\FM\07AUN1.SGM
07AUN1
Agencies
[Federal Register Volume 82, Number 150 (Monday, August 7, 2017)]
[Notices]
[Pages 36830-36834]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-16439]
[[Page 36830]]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-471N]
Proposed Aggregate Production Quotas for Schedule I and II
Controlled Substances and Assessment of Annual Needs for the List I
Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2018
AGENCY: Drug Enforcement Administration, Department of Justice.
ACTION: Notice with request for comments.
-----------------------------------------------------------------------
SUMMARY: The Drug Enforcement Administration (DEA) proposes to
establish the 2018 aggregate production quotas for controlled
substances in schedules I and II of the Controlled Substances Act and
assessment of annual needs for the list I chemicals ephedrine,
pseudoephedrine, and phenylpropanolamine.
DATES: Interested persons may file written comments on this notice in
accordance with 21 CFR 1303.11(c) and 1315.11(d). Electronic comments
must be submitted, and written comments must be postmarked, on or
before September 6, 2017. Commenters should be aware that the
electronic Federal Docket Management System will not accept comments
after 11:59 p.m. Eastern Time on the last day of the comment period.
Based on comments received in response to this notice, the
Administrator may hold a public hearing on one or more issues raised.
In the event the Administrator decides in his sole discretion to hold
such a hearing, the Administrator will publish a notice of any such
hearing in the Federal Register. After consideration of any comments or
objections, or after a hearing, if one is held, the Administrator will
publish in the Federal Register a final order establishing the 2018
aggregate production quotas for schedule I and II controlled
substances, and an assessment of annual needs for the list I chemicals
ephedrine, pseudoephedrine, and phenylpropanolamine.
ADDRESSES: To ensure proper handling of comments, please reference
``Docket No. DEA-471N'' on all correspondence, including any
attachments. The Drug Enforcement Administration encourages that all
comments be submitted electronically through the Federal eRulemaking
Portal which provides the ability to type short comments directly into
the comment field on the Web page or attach a file for lengthier
comments. Please go to https://www.regulations.gov and follow the online
instructions at that site for submitting comments. Upon completion of
your submission you will receive a Comment Tracking Number for your
comment. Please be aware that submitted comments are not
instantaneously available for public view on Regulations.gov. If you
have received a Comment Tracking Number, your comment has been
successfully submitted and there is no need to resubmit the same
comment. Paper comments that duplicate electronic submissions are not
necessary and are discouraged. Should you wish to mail a paper comment
in lieu of an electronic comment, it should be sent via regular or
express mail to: Drug Enforcement Administration, Attention: DEA
Federal Register Representative/DRW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
FOR FURTHER INFORMATION CONTACT: Michael J. Lewis, Diversion Control
Division, Drug Enforcement Administration; Mailing Address: 8701
Morrissette Drive, Springfield, Virginia 22152, Telephone: (202) 598-
6812.
SUPPLEMENTARY INFORMATION:
Posting of Public Comments
Please note that all comments received in response to this docket
are considered part of the public record. They will, unless reasonable
cause is given, be made available by the Drug Enforcement
Administration (DEA) for public inspection online at https://www.regulations.gov. Such information includes personal identifying
information (such as your name, address, etc.) voluntarily submitted by
the commenter.
The Freedom of Information Act (FOIA) applies to all comments
received. If you want to submit personal identifying information (such
as your name, address, etc.) as part of your comment, but do not want
it to be made publicly available, you must include the phrase
``PERSONAL IDENTIFYING INFORMATION'' in the first paragraph of your
comment. You must also place all the personal identifying information
you do not want made publicly available in the first paragraph of your
comment and identify what information you want redacted.
If you want to submit confidential business information as part of
your comment, but do not want it to be made publicly available, you
must include the phrase ``CONFIDENTIAL BUSINESS INFORMATION'' in the
first paragraph of your comment. You must also prominently identify
confidential business information to be redacted within the comment.
Comments containing personal identifying information or
confidential business information identified and located as directed
above will generally be made available in redacted form. If a comment
contains so much confidential business information or personal
identifying information that it cannot be effectively redacted, all or
part of that comment may not be made publicly available. Comments
posted to https://www.regulations.gov may include any personal
identifying information (such as name, address, and phone number)
included in the text of your electronic submission that is not
identified as directed above as confidential.
An electronic copy of this document is available at https://www.regulations.gov for easy reference.
Legal Authority
Section 306 of the Controlled Substances Act (CSA) (21 U.S.C. 826)
requires the Attorney General to establish aggregate production quotas
for each basic class of controlled substance listed in schedules I and
II and for the list I chemicals ephedrine, pseudoephedrine, and
phenylpropanolamine. The Attorney General has delegated this function
to the Administrator of the DEA pursuant to 28 CFR 0.100.
Analysis for Proposed 2018 Aggregate Production Quotas and Assessment
of Annual Needs
The proposed year 2018 aggregate production quotas and assessment
of annual needs represent those quantities of schedule I and II
controlled substances, and the list I chemicals ephedrine,
pseudoephedrine, and phenylpropanolamine, to be manufactured in the
United States in 2018 to provide for the estimated medical, scientific,
research, and industrial needs of the United States, lawful export
requirements, and the establishment and maintenance of reserve stocks.
These quotas include imports of ephedrine, pseudoephedrine, and
phenylpropanolamine, but do not include imports of controlled
substances for use in industrial processes.
In determining the proposed 2018 aggregate production quotas and
assessment of annual needs, the Acting Administrator has taken into
account the criteria pursuant to 21 U.S.C. 826(a) and in accordance
with 21 CFR 1303.11 (aggregate production quotas for controlled
substances) and 21 CFR 1315.11 (assessment of annual needs for
ephedrine, pseudoephedrine, and
[[Page 36831]]
phenylpropanolamine). The DEA proposes the aggregate production quotas
and assessment of annual needs for 2018 by considering: (1) Total net
disposal of each class or chemical by all manufacturers and chemical
importers during the current and two preceding years; (2) trends in the
national rate of net disposal of the class or chemical; (3) total
actual (or estimated) inventories of the class or chemical and of all
substances manufactured from the class or chemical, and trends in
inventory accumulation; (4) projected demand for each class or chemical
as indicated by procurement and import quotas requested in accordance
with 21 CFR 1303.12, 1315.32, and 1315.34; and (5) other factors
affecting medical, scientific, research, and industrial needs of the
United States and lawful export requirements, as the Acting
Administrator finds relevant. These quotas do not include imports of
controlled substances for use in industrial processes.
Other factors the Acting Administrator considered in calculating
the aggregate production quotas, but not the assessment of annual
needs, include product development requirements of both bulk and
finished dosage form manufacturers, and other pertinent information. In
determining the proposed 2018 assessment of annual needs, the DEA used
the calculation methodology previously described in the 2010 and 2011
assessment of annual needs (74 FR 60294, Nov. 20, 2009, and 75 FR
79407, Dec. 20, 2010, respectively).
The Acting Administrator, therefore, proposes to establish the 2018
aggregate production quotas for certain schedule I and II controlled
substances and assessment of annual needs for the list I chemicals
ephedrine, pseudoephedrine, and phenylpropanolamine, expressed in grams
of anhydrous acid or base, as follows:
------------------------------------------------------------------------
Proposed 2018
quotas
Basic class ---------------
(g)
------------------------------------------------------------------------
Schedule I
------------------------------------------------------------------------
1-(1-Phenylcyclohexyl)pyrrolidine....................... 10
1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201)....... 30
1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694)...... 30
1-[1-(2-Thienyl)cyclohexyl]piperidine................... 15
1-Benzylpiperazine...................................... 25
1-Methyl-4-phenyl-4-propionoxypiperidine................ 2
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E)........ 30
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D)....... 30
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N)....... 30
2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C-P)..... 30
2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)................ 30
2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2- 25
methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B;
Cimbi-36)..............................................
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C)....... 30
2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2- 25
methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C;
Cimbi-82)..............................................
2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I)......... 30
2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2- 30
methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I;
Cimbi-5)...............................................
2,5-Dimethoxy-4-ethylamphetamine (DOET)................. 25
2,5-Dimethoxy-4-n-propylthiophenethylamine.............. 25
2,5-Dimethoxyamphetamine................................ 25
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2) 30
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C- 30
T-4)...................................................
3,4,5-Trimethoxyamphetamine............................. 25
3,4-Methylenedioxyamphetamine (MDA)..................... 55
3,4-Methylenedioxymethamphetamine (MDMA)................ 50
3,4-Methylenedioxy-N-ethylamphetamine (MDEA)............ 40
3,4-Methylenedioxy-N-methylcathinone (methylone)........ 40
3,4-Methylenedioxypyrovalerone (MDPV)................... 35
3-FMC; 3-Fluoro-N-methylcathinone....................... 25
3-Methylfentanyl........................................ 30
3-Methylthiofentanyl.................................... 30
4-Bromo-2,5-dimethoxyamphetamine (DOB).................. 25
4-Bromo-2,5-dimethoxyphenethylamine (2-CB).............. 25
4-Fluoroisobutyryl fentanyl............................. 30
4-FMC; Flephedrone...................................... 25
4-MEC; 4-Methyl-N-ethylcathinone........................ 25
4-Methoxyamphetamine.................................... 150
4-Methyl-2,5-dimethoxyamphetamine (DOM)................. 25
4-Methylaminorex........................................ 25
4-Methyl-N-methylcathinone (mephedrone)................. 45
4-Methyl-[alpha]-pyrrolidinopropiophenone (4-MePPP)..... 25
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]- 50
phenol.................................................
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]- 40
phenol (cannabicyclohexanol or CP-47,497 C8-homolog)...
5F-ADB; 5F-MDMB-PINACA (methyl 2-(1-(5-fluoropentyl)-1H- 30
indazole-3-carboxamido)-3,3-dimethylbutanoate).........
5F-AMB (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3- 30
carboxamido)-3-methylbutanoate)........................
5F-APINACA; 5F-AKB48 (N-(adamantan-1-yl)-1-(5- 30
fluoropentyl)-1H-indazole-3-carboxamide)...............
5-Fluoro-PB-22; 5F-PB-22................................ 20
5-Fluoro-UR144, XLR11 ([1-(5-fluoro-pentyl)-1Hindol-3- 25
yl](2,2,3,3-tetramethylcyclopropyl)methanone...........
5-Methoxy-3,4-methylenedioxyamphetamine................. 25
5-Methoxy-N,N-diisopropyltryptamine..................... 25
[[Page 36832]]
5-Methoxy-N,N-dimethyltryptamine........................ 25
AB-CHMINACA............................................. 30
AB-FUBINACA............................................. 50
AB-PINACA............................................... 30
ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1- 30
(4-fluorobenzyl)-1H-indazole-3-carboxamide)............
Acetyl Fentanyl......................................... 100
Acetyl-alpha-methylfentanyl............................. 30
Acetyldihydrocodeine.................................... 30
Acetylmethadol.......................................... 2
ADB-PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1- 50
pentyl-1H-indazole-3-carboxamide)......................
AH-7921................................................. 30
Allylprodine............................................ 2
Alphacetylmethadol...................................... 2
alpha-Ethyltryptamine................................... 25
Alphameprodine.......................................... 2
Alphamethadol........................................... 2
alpha-Methylfentanyl.................................... 30
alpha-Methylthiofentanyl................................ 30
alpha-Methyltryptamine (AMT)............................ 25
alpha-Pyrrolidinobutiophenone ([alpha]-PBP)............. 25
alpha-Pyrrolidinopentiophenone ([alpha]-PVP)............ 25
Aminorex................................................ 25
APINCA, AKB48 (N-(1-adamantyl)-1-pentyl-1H-indazole-3- 25
carboxamide)...........................................
Benzylmorphine.......................................... 30
Betacetylmethadol....................................... 2
beta-Hydroxy-3-methylfentanyl........................... 30
beta-Hydroxyfentanyl.................................... 30
beta-Hydroxythiofentanyl................................ 30
Betameprodine........................................... 2
Betamethadol............................................ 4
Betaprodine............................................. 2
Bufotenine.............................................. 3
Butylone................................................ 25
Butyryl fentanyl........................................ 30
Cathinone............................................... 24
Codeine methylbromide................................... 30
Codeine-N-oxide......................................... 192
Desomorphine............................................ 25
Diethyltryptamine....................................... 25
Difenoxin............................................... 8,225
Dihydromorphine......................................... 1,000,160
Dimethyltryptamine...................................... 35
Dipipanone.............................................. 5
Etorphine............................................... 30
Fenethylline............................................ 30
Furanyl fentanyl........................................ 30
gamma-Hydroxybutyric acid............................... 37,130,000
Heroin.................................................. 45
Hydromorphinol.......................................... 40
Hydroxypethidine........................................ 2
Ibogaine................................................ 30
JWH-018 and AM678 (1-Pentyl-3-(1-naphthoyl)indole)...... 35
JWH-019 (1-Hexyl-3-(1-naphthoyl)indole)................. 45
JWH-073 (1-Butyl-3-(1-naphthoyl)indole)................. 45
JWH-081 (1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole)..... 30
JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole)....... 30
JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1- 35
naphthoyl)indole)......................................
JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole)....... 30
JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole)...... 30
JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole)....... 30
Lysergic acid diethylamide (LSD)........................ 40
MAB-CHMINACA; ADB-CHMINACA (N-(1-amino-3,3-dimethyl-1- 30
oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-
carboxamide)...........................................
MDMB-CHMICA; MMB-CHMINACA (methyl 2-(1- 30
(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-
dimethylbutanoate).....................................
MDMB-FUBINACA (methyl 2-(1-(4-fluorobenzyl)-1H-indazole- 30
3-carboxamido)-3,3-dimethylbutanoate)..................
Marihuana............................................... 443,680
Mecloqualone............................................ 30
Mescaline............................................... 25
Methaqualone............................................ 60
Methcathinone........................................... 25
[[Page 36833]]
Methyldesorphine........................................ 5
Methyldihydromorphine................................... 2
Morphine methylbromide.................................. 5
Morphine methylsulfonate................................ 5
Morphine-N-oxide........................................ 150
N,N-Dimethylamphetamine................................. 25
Naphyrone............................................... 25
N-Ethyl-1-phenylcyclohexylamine......................... 5
N-Ethylamphetamine...................................... 24
N-Hydroxy-3,4-methylenedioxyamphetamine................. 24
Noracymethadol.......................................... 2
Norlevorphanol.......................................... 55
Normethadone............................................ 2
Normorphine............................................. 40
Para-fluorofentanyl..................................... 25
Parahexyl............................................... 5
PB-22; QUPIC............................................ 20
Pentedrone.............................................. 25
Pentylone............................................... 25
Phenomorphan............................................ 2
Pholcodine.............................................. 5
Psilocybin.............................................. 30
Psilocyn................................................ 50
SR-18 and RCS-8 (1-Cyclohexylethyl-3-(2- 45
methoxyphenylacetyl)indole)............................
SR-19 and RCS-4 (1-Pentyl-3-[(4-methoxy)-benzoyl]indole) 30
Tetrahydrocannabinols................................... 384,460
Thiofentanyl............................................ 25
THJ-2201 ([1-(5-fluoropentyl)-1H-indazol-3- 30
yl](naphthalen-1-yl)methanone).........................
Tilidine................................................ 25
Trimeperidine........................................... 2
UR-144 (1-pentyl-1H-indol-3-yl)(2,2,3,3- 25
tetramethylcyclopropyl)methanone.......................
U-47700................................................. 30
------------------------------------------------------------------------
Schedule II
------------------------------------------------------------------------
1-Phenylcyclohexylamine................................. 4
1-Piperidinocyclohexanecarbonitrile..................... 4
4-Anilino-N-phenethyl-4-piperidine (ANPP)............... 1,342,320
Alfentanil.............................................. 2,538
Alphaprodine............................................ 2
Amobarbital............................................. 18,894
Amphetamine (for conversion)............................ 11,280,000
Amphetamine (for sale).................................. 39,856,000
Carfentanil............................................. 20
Cocaine................................................. 92,120
Codeine (for conversion)................................ 15,040,000
Codeine (for sale)...................................... 40,015,800
Dextropropoxyphene...................................... 35
Dihydrocodeine.......................................... 264,140
Dihydroetorphine........................................ 2
Diphenoxylate (for conversion).......................... 14,100
Diphenoxylate (for sale)................................ 770,800
Ecgonine................................................ 88,134
Ethylmorphine........................................... 30
Etorphine hydrochloride................................. 32
Fentanyl................................................ 1,342,320
Glutethimide............................................ 2
Hydrocodone (for conversion)............................ 114,680
Hydrocodone (for sale).................................. 50,348,280
Hydromorphone........................................... 4,547,720
Isomethadone............................................ 30
Levo-alphacetylmethadol (LAAM).......................... 5
Levomethorphan.......................................... 30
Levorphanol............................................. 12,126
Lisdexamfetamine........................................ 17,869,000
Meperidine.............................................. 2,717,540
Meperidine Intermediate--A.............................. 5
Meperidine Intermediate--B.............................. 30
Meperidine Intermediate--C.............................. 5
Metazocine.............................................. 15
Methadone (for sale).................................... 22,278,000
[[Page 36834]]
Methadone Intermediate.................................. 24,064,000
Methamphetamine......................................... 1,446,754
------------------------------------------------------------------------
[900,000 grams of levo-desoxyephedrine for use in a non-controlled, non-
prescription product; 600,000 grams for methamphetamine mostly for
conversion to a schedule III product; and 39,100 grams for
methamphetamine (for sale)]
------------------------------------------------------------------------
Methylphenidate......................................... 60,724,000
Morphine (for conversion)............................... 4,089,000
Morphine (for sale)..................................... 33,958,440
Nabilone................................................ 17,860
Noroxymorphone (for conversion)......................... 14,044,540
Noroxymorphone (for sale)............................... 376,000
Opium (powder).......................................... 84,600
Opium (tincture)........................................ 564,000
Oripavine............................................... 24,534,000
Oxycodone (for conversion).............................. 2,453,400
Oxycodone (for sale).................................... 95,692,000
Oxymorphone (for conversion)............................ 20,962,000
Oxymorphone (for sale).................................. 3,395,280
Pentobarbital........................................... 25,850,000
Phenazocine............................................. 5
Phencyclidine........................................... 35
Phenmetrazine........................................... 25
Phenylacetone........................................... 40
Racemethorphan.......................................... 5
Racemorphan............................................. 5
Remifentanil............................................ 2,820
Secobarbital............................................ 161,682
Sufentanil.............................................. 1,880
Tapentadol.............................................. 18,388,280
Thebaine................................................ 94,000,000
------------------------------------------------------------------------
List I Chemicals
------------------------------------------------------------------------
Ephedrine (for conversion).............................. 47,000
Ephedrine (for sale).................................... 4,136,000
Phenylpropanolamine (for conversion).................... 14,100,000
Phenylpropanolamine (for sale).......................... 7,990,000
Pseudoephedrine (for conversion)........................ 40
Pseudoephedrine (for sale).............................. 169,200,000
------------------------------------------------------------------------
The Acting Administrator further proposes that aggregate production
quotas for all other schedule I and II controlled substances included
in 21 CFR 1308.11 and 1308.12 remain at zero. In accordance with 21 CFR
1303.13 and 21 CFR 1315.13, upon consideration of the relevant factors,
the Acting Administrator may adjust the 2018 aggregate production
quotas and assessment of annual needs as needed.
Conclusion
After consideration of any comments or objections, or after a
hearing, if one is held, the Acting Administrator will issue and
publish in the Federal Register a final order establishing the 2018
aggregate production quota for controlled substances in schedules I and
II and establishing an assessment of annual needs for the list I
chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, 21 CFR
1303.11(c) and 1315.11(f).
Dated: July 27, 2017.
Chuck Rosenberg,
Acting Administrator.
[FR Doc. 2017-16439 Filed 8-4-17; 8:45 am]
BILLING CODE 4410-09-P